Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon(BC Cancer Agency), Marc Tischkowitz(Jewish General Hospital), Helen Mackay(Princess Margaret Cancer Centre), Kenneth D. Swenerton(BC Cancer Agency), André Robidoux(Université de Montréal), Katia Tonkin, Hal W. Hirte(Juravinski Cancer Centre), David G. Huntsman(BC Cancer Agency), Mark Clemons(Princess Margaret Cancer Centre), C. Blake Gilks(University of British Columbia), Rinat Yerushalmi(BC Cancer Agency), Euan Macpherson(AstraZeneca (United Kingdom)), James Carmichael(AstraZeneca (United Kingdom)), Amit M. Oza(Princess Margaret Cancer Centre)
Cited by 1,112
Abstract
Related Papers
No related papers found
Powered by citation graph analysis